Clinical Trial Update: Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a combination of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: European Myeloma Network B.V. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED